Fuchs Henry J's Form 4 filing
Mirati Therapeutics, Inc. (MRTX) · filed Feb 14, 2022
- Accession no.
- 0001214659-22-002681
- Filed
- Feb 14, 2022
- Trade date
- Feb 11, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.16M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fuchs Henry JCIK 0001197355 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 11, 2022 | Common Stock | MOption exerciseAcquired | +6,000 | $20.54 | +$123,240 | 12,021 | Direct | |
| Feb 11, 2022 | Common Stock | MOption exerciseAcquired | +5,000 | $20.54 | +$102,700 | 17,021 | Direct | |
| Feb 11, 2022 | Common Stock | SSaleDisposed | −2,090 | $104.76F2 | −$218,948.4 | 14,931 | Direct | |
| Feb 11, 2022 | Common Stock | SSaleDisposed | −8,700 | $105.80F3 | −$920,460 | 6,231 | Direct | |
| Feb 11, 2022 | Common Stock | SSaleDisposed | −210 | $106.34F4 | −$22,331.4 | 6,021 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 11, 2022 | Common Stock | MOption exerciseDisposed | −6,000 | $0.00 | $0 | 0 | Direct | |
| Feb 11, 2022 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $104.23 to $105.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $105.28 to $106.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $106.33 to $106.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.